Non-Insulin Diabetes Medications

A growing arsenal of non-insulin diabetes medications is expanding therapeutic options beyond traditional insulin therapy. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant benefits in glycemic control while reducing cardiovascular risks. DPP-4 inhibitors offer a convenient oral alternative, particularly for patients seeking weight-neutral treatments. Recent advancements include combination therapies that target multiple metabolic pathways simultaneously, enhancing efficacy while minimizing side effects. Additionally, bile acid sequestrants, dopamine agonists, and amylin analogs provide novel mechanisms for improving insulin sensitivity. With continued research into incretin-based therapies and dual-agonist formulations, non-insulin medications are playing a crucial role in personalized diabetes management.

Committee Members
Speaker at Diabetes  2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes  2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes  2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes  2026 - Wan Rosli Wan Ishak

Wan Rosli Wan Ishak

Universiti Sains Malaysia, Malaysia
Diabetes 2026 Speakers
Speaker at Diabetes  2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes  2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes  2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes  2026 - David Navazio

David Navazio

Gentell, United States
Speaker at Diabetes  2026 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes  2026 - David Petch

David Petch

utR Biotech, Canada
Tags

Submit your abstract Today

YouTube
WhatsAppWhatsApp